Preoperative chemotherapy and endocrine therapy in patients with breast cancer

Clinical Breast Cancer

Volumn 5, Issue 3, 2004, Pages 198-207

  Hönig, Arnd ^a   Rieger, Lorenz ^a   Sutterlin, Marc ^a   Dietl, Johannes ^a   Solomayer, Erich Franz ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Aromatase inhibitors; Cancer biology; Local recurrence; Neoadjuvant therapy; Prognostic factors

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DISEASE MARKER; DNA MICROARRAY; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG RESPONSE; FEASIBILITY STUDY; GENE EXPRESSION PROFILING; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT MONITORING; PREOPERATIVE CARE; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT PLANNING;

EID: 12344282910     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.023     Document Type: Review

References (95)

1. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease. Oncologist 2002; 7:239-245.
2. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
3. NSABP. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27. Breast Cancer Res Treat 2001; 69(suppl):210a (Abstract #5).
4. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3:S69-S74.
5. Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast cancer. Oncology 2002; 16:871-898.
6. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
7. van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-4237.
8. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 1997; 15:2483-2493.
9. Broet P, Scholl SM, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial of a randomized trial. Breast Cancer Res Treat 1999; 58:151-156.
10. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10:47-52.
11. Gunduz N, Fisher B, Saffer E. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39:3861-3865.
12. Fisher B, Gebhardt M, Saffer E. Further observations on the inhibition of tumor growth by C. parvum with cyclophosphamide: Effect of treatment prior to primary tumor removal on the growth of distant tumor. Cancer 1979; 43:451-458.
13. Fisher B, Gunduz N, Saffer E. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 49:1488-1492.
14. Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49:1996-2001.
15. Fisher B, Saffer E, Rudock C, et al. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989; 49:2002-2004.
16. Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001; 61:2207-2211.
17. Wang J, Buchholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002; 94:3107-3114.
18. Billgren A, Rutqvist L, Tani E, et al. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse free survival. Acta Oncol 1999; 38:597-601.
19. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6:4610-4617.
20. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002; 9:183-195.
21. Perou CM, Sortie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
22. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874
23. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 19:1999-2009.
25. Chang JC, Wooten EC, Tsimezon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362:362-369.
26. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 2002; 38:2214-2221.
27. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989; 124:21-25.
28. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86:1041-1046.
29. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176:502-509.
30. Scholl SM, Pierga JY, Asselain B, et al. Breast tumours response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995; 31A:1969-1995.
31. Fisher B, Mamounas EP. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13:537-540.
32. Scholl SM, Beuzeboc P, Harris AL, et al. Is primary chemotherapy useful for all patients with primary invasive breast cancer? In Senn HJ, Gelber RD, Goldhirsch A, et al, eds. Adjuvant Therapy of Primary Breast Cancer VI. Berlin: Springer, 1998:217-226.
33. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
34. Honig A, Solomayer EF, Sinn HP et al. Pathological complete remission is not the best prognostic-factor in patients with breast cancer treated by preoperative chemotherapy. Breast Cancer Res Treat 2002; 76(suppl):S52 (Abstract #158).
35. Gajdos C, Tartter PI, Estabrook A, et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80:4-11.
36. Buchholz TA, Hill BS, Tucker SL, et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001; 7:413-420.
37. Borresen-Dale AL. TP53 and Breast cancer. Hum Mutation 2003; 21:292-300.
38. Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: a review of the literature involving over 9000 patients. Appl Immunohistochem 2002; 4:106-116.
39. Norberg T, Lennerstrand J, Inganas M, et al. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998; 79:376-383.
40. Geisler S, Loaning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61:2505-2512.
41. Blaszyk H, Hartmann A, Cunningham JM, et al. A prospective trial of Midwest breast cancer patients: a p53 mutation is the most important predictor of adverse outcome. Int J Cancer 2000; 89:32-38.
42. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80:1968-1973.
43. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002; 3:183-195.
44. Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3:593-600.
45. Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 1996; 16:3105-3110.
46. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation to outcome. Br J Cancer 2003; 88:406-412.
47. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictor of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999; 17:3058-3063.
48. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998; 352:930-942.
49. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351:1451-1467.
50. Bonadonna G, Brusamolino E, Valagusa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294:405-410.
51. Green MC, Buzdar AU, Smith T. Weekly paclitaxel followed by FAC in the neoadjuvant setting provides improved pathological complete remission rates compared to standard paclitaxel followed by FAC therapy: Preliminary results of an on going prospective clinical trial. Proc Am Soc Clin Oncol 2001; 17:101a (Abstract #129a).
52. Sanchez-Rovira P, Jaen A, Duenas R, et al. Neoadjuvant gemcitabine therapy for breast cancer. Clin Breast Cancer 2002; 3(suppl 1):39-44.
53. Besse B, Spano JP. Gemcitabine and breast cancer. Bull Cancer 2002; 89(suppl):S107-S114.
54. Huober JB, Geberth M, Krauss K, et al. Gemcitabine (G), epirubicin (E) and docetaxel (doc) as neoadjuvant chemotherapy (NCT) for patients (pts) with primary breast cancer (BC): results of a phase I/II trial. Proc Am Soc Clin Oncol 2003; 22:87 (Abstract #346).
55. Brand AC, Levy E, Feuilhade F, et al. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study. Am J Clin Oncol 2002; 25:303-307.
56. Gelmon K, Arnold A, Verma S, et al. Pharmacocinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks. Proc Am Soc Clin Oncol 2001; 20: (Abstract #271).
57. Evans T, Gould A, Foster E, et al. Phase III randomised trial of adriamycin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer: an ACCOG study. Proc Am Soc Clin Oncol 2002; 20:35a (Abstract #136).
58. Citron M, Berry D, Cirrincione C, et al. Superiority of dose-dense. (DD) over conventional scheduling and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (SS) for node-positive breast cancer (CALBG 9741, INT C9741) Breast Cancer Res Treat 2002; 76:S32 (Abstract #15).
59. Jakisch C, von Minckwitz G, Eidtmann H, et al. Dose-dense bi-weekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide and docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 2002; 4:276-280.
60. Untch M, Konecny G, Ditsch N, et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc Am Soc Clin Oncol 2002; 21:34a (Abstract #133).
61. Wolmark N, Wang J, Mammounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
62. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002; 236:295-303.
63. Veronesi U, Bonadonna G, Zurrida S. et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222:612-618.
64. Galmarini CM, Garbvesky C, Galmarini D, et al. Clinical outcome and prognosis of patients with inflammatory breast cancer. Am J Clin Oncol 2002; 25:172-177.
65. Rouzier R, Extra JM, Carton M, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 2001; 19:3828-3835.
66. Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002; 20:17-23.
67. Buchholz TA, Katz A, Strom EA, et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2002; 53:880-888.
68. Ellis P, Ashley S, Walsh G, et al. Identification of clinical factors predicting outcome following primary chemotherapy for operable breast cancer. Breast 1999; 8:235.
69. Gerlach B, Audretsch W, Gogolin F, et al. Remission rates in breast cancer treated with preoperative chemotherapy and radiotherapy. Strahlenther Onko 2003; 179:306-311.
70. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-2608.
71. Nardone L, Ausili-Cefaro G, Palazzoni G, et al. Preoperative radiotherapy in the conservative treatment for breast cancer. Rays 1997; 22:417-424.
72. Ikeda T, Jinno H, Matsu A, et al. The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer 2002; 9:8-14.
73. Ragaz J. The Green/Hortobagyi article reviewed. Oncology 2002; 16:871-898.
74. Shanon C, Smith I. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hem 2003; 45:77-90.
75. Murray N. Timing of thoracic irradiation for limited small-cell lung cancer. J Clin Oncol 1998; 16:1633-1635.
76. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Letrozole Neo-Adjuvant Breast Cancer Study Group. Ann Oncol 2001; 12:527-532.
77. Dixon JM, Love CDB, Bellamy COC, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001; 66:191-199.
78. Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant Anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000; 6:2229-2235.
79. Dixon JM, Anderson T, Miller WR. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc Am Soc Clin Oncol 2001; 20:40b (Abstract #1908).
80. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-3816.
81. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002 9(suppl 2):9-15.
82. Milla-Santos A, Milla I, Rallo L, et al. Anastrozole as neoadjuvant therapy for hormone-dependent locally advanced breast cancer in postmenopausal patients. Proc Am Soc Clin Oncol 2002; 21:40a (Abstract #156).
83. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29:231-245.
84. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002 20:1467-1472.
85. Lee H, Jiang F, Wang Q, et al. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 2000; 14:1882-1896.
86. Anderson TJ, Dixon JM, Stuart M, et al. Effect of neoadjuvant treatment with anastrozole on tumor histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002; 87:334-338.
87. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12:1527-1532.
88. Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: medical perspectives. Clin Cancer Res 2001; 7:4388-4391.
89. Raab G, von Minckwitz G, Serban C, et al. Gepardo (German Preoperative Adriamycin Docetaxel) trial comparing a combination of dose-intensified Adriamycin and docetaxel with or without tamoxifen as preoperative, therapy in patients with operable breast cancer. Proc Am Soc Clin Oncol 1999; 18:100a (Abstract #377).
90. Raab G, von Minckwitz G, Schuette M, et al. Predictive value of primary systemic chemotherapy (PSC) induced anemia for pathologic complete response (pCR) in operable breast cancer: Results from the GEPARDUO trial. Proc Am Soc Clin Oncol 2003; 22:901 (Abstract #3623).
91. Eiermann W, Sabadell D, Baselga J, et al. European cooperative trial in operable breast cancer (ECTO): No increased risk of local breast tumor recurrence (LBR) as first and only event after primary systemic therapy (PST). Proc Am Soc Clin Oncol 2003; 22:10 (Abstract #37).
92. Von Minckwitz G, Raab G, Blohmer JU, et al, for the GABG. Primary chemotherapy adapted on in-vivo-chemosensitivity in patients with primary breast cancer. The pilot GEPARTRIO study. Proc Am Soc Clin Oncol 2003; 22:22 (Abstract #85).
93. Ruhl I, Bauerfeind I, Kahlert S, et al. Neoadjuvant therapy of breast cancer. Gynakol Geburtshilfliche Rundsch 2004; 44:92-101.
94. Wolf C, Kümper S, Krainick U, et al. Exemestane with/without fractionated epirubicin as preoperative treatment for patients with primary breast cancer: an exploratory phase II study of the GENARI study group. Proc Am Soc Clin Oncol 2002; 21:44b (Abstract #1989).
95. Sartor CI, Fitzgerald TJ, Laurie F, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344. Proc Am Soc Clin Oncol 2003; 22:10 (Abstract #38).